Development Pipeline




Overview

OncoMed currently has three therapeutic candidates in active clinical development targeting cancer stem cell pathways and immuno-oncology. OncoMed is also pursuing discovery of additional novel approaches to cancer treatment, including new immuno-oncology therapeutic candidates. All of the therapeutic candidates in our pipeline were discovered by OncoMed scientists.

 

Navicixizumab (Anti-DLL4/VEGF bispecific, OMP-305B83)

Navicixizumab, OncoMed's anti-DLL4/VEGF bispecific antibody targets both DLL4 in the Notch cancer stem cell pathway and vascular endothelial growth factor (VEGF) receptors. This antibody is intended to have anti-angiogenic plus anti-cancer stem cell and immunomodulatory activity. In a Phase 1a clinical trial, navicixizumab demonstrated single-agent anti-tumor activity and was safe enough to be administered on a continuous basis. OncoMed has initiated two Phase 1b clinical trials to assess the safety, preliminary efficacy, immunogenicity and pharmacokinetics of navicixizumab in combination with standard of care chemotherapy in ovarian and colorectal cancers.

Information on navicixizumab clinical trials is available here: Navicixizumab ClinicalTrials.gov.

This program is part of OncoMed's collaboration with Celgene Corporation.

Public presentations on studies if navicixizumab include:

 

Anti-TIGIT (OMP-313M32)

TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor that is thought to stop T-cells from attacking tumor cells, similar to the inhibitory protein PD-1. OncoMed's anti-TIGIT therapeutic candidate is intended to activate the immune system through multiple mechanisms and enable anti-tumor activity. A Phase 1 clinical trial of OncoMed's anti-TIGIT candidate is currently enrolling patients.

Information on OncoMed's anti-TIGIT clinical program is available here: OMP-313M32 ClinicalTrials.gov.

This program is part of OncoMed's collaboration with Celgene Corporation.

Public presentations of data from OncoMed's anti-TIGIT program include:

 

GITRL-Fc trimer (OMP-336B11)

GITRL is a member of the tumor necrosis factor (TNF) family of ligands and functions to activate the co-stimulatory receptor GITR (glucocorticoid-induced tumor necrosis factor receptor) to enhance T-cell modulated immune responses. OncoMed's GITRL-Fc therapeutic candidate is engineered using a novel single-gene linkerless GITRL trimer technology that is designed to enable effective GITR activation. In preclinical models, OncoMed's GITRL-Fc therapeutic candidate has achieved robust anti-tumor immune responses alone and in combingation with other immuno-oncology agents. A Phase I clinical trial of OncoMed's GITRL-Fc therapeutic candidate is currently active and enrolling patients.

Information on OncoMed's GITRL clinical program is available here: OMP-336B11 ClinicalTrials.gov.

Public presentations of data from OncoMed's GITRL program include:

 

Rosmantuzumab (Anti-RSPO3, OMP-131R10)

In 2007, OncoMed identified that the R-spondin (RSPO) ligands signal through the LGR receptor family and has since identified antibodies to proteins in this family that modulate RSPO-LGR signaling. RSPO appears to be an oncogenic driver in several tumor types, particularly colon cancer, and is associated with the activation of Wnt signaling and tumorigenesis. Rosmantuzumab (anti-RSPO3, OMP-131R10) is a monoclonal antibody targeting the RSPO-LGR pathway, and was recently studied in a Phase 1a/b clinical trial, but the trial failed to provide compelling evidence of clinical benefit. OncoMed is currently discussing next steps with its partner, Celgene Corporation.

Information on OncoMed's Rosmantuzumab clinical program is available here: Rosmantuzumab ClinicalTrials.gov.

This program is part of OncoMed’s collaboration with Celgene Corporation.

Public presentations on rosmantuzumab include: